Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trialYi‐Long Wu, Tony Mok, Xiangdong Zhou et al.|The Lancet Oncology|2017Cited by 1.2k
A Protective Effect of Pirfenidone in Lung Fibroblast–Endothelial Cell Network via Inhibition of Rho-Kinase ActivityYusuke Nakamura, Seiji Niho|Biomedicines|2023Cited by 9